You are here: Industry Insights > PD-1

News List

AlloHSCT Feasible After PD-1, PD-L1 mAb in Hodgkin Lymphoma drugs
December 25, 2019
Allogeneic hematopoietic stem cell transplantation (alloHSCT) performed after programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAB) treatment seems feasible for patients with classical Hodgkin lymphoma with ...
FDA Grants Accelerated Approval to enfortumab vedotin-ejfv americanpharmaceuticalreview
December 24, 2019
The Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (PADCEV, Astellas Pharma) for adult patients with locally advanced or ...
Agenus Commences Trial of Next-Gen CTLA-4 with PD-1 Antibody americanpharmaceuticalreview
December 20, 2019
Agenus announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody, in combination with balstilimab, Agenus' PD-1 inhibitor.
China has Entered the Era of Tumor Immunotherapy: Updates on the R&D Progress of Anti-PD-(L)1 Antibodies PharmaSources/1℃
March 06, 2019
2018 was the first year of the tumor immunotherapy in China. The new era of tumor immunotherapy has begun in China with the marketing of anti-PD-(L)1 antibodies represented by Opdivo, Keytruda, and Tuoyi, etc. in China.
Cancer-killing virus plus PD-1 and MEK inhibitors make for a 3-pronged attack on melanoma fiercebiotech
December 26, 2018
When Amgen’s cancer-killing virus Imlygic—also known as T-Vec—was approved by the FDA in late 2015, experts expected it would work best in combination strategies for melanoma.....
AstraZeneca's Imfinzi immunotherapy combo fails to show benefit in lung cancer pharmafile
November 19, 2018
AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a recent Phase 3 trial in the treatment
Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron pharmafocusasia
November 13, 2018
Ziopharm Oncology, Inc.,today announced a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex in combination with Regeneron’s PD-1 antibody Libtayo® (cemiplimab-rwlc) to treat patients with re
The Most Comprehensive Summary Ever! About the Chinese-produced Anti-PD-1/PD-L1 Drugs Caicai
April 13, 2018
The anti-PD-1 monoclonal antibody JS001 of Junshi has been completed the first patient administration of Phase I clinical trial in the U.S. several days ago, which has aroused wide attention from the insiders.
Opdivo May Be the First Marketed in China, Chinese Pharmaceutical Enterprises are Catching up Fast! Zhixing
January 17, 2018
Anti-PD-1 monoclonal antibodies are very popular with pharmaceutical enterprises, however, it is hard to find such monoclonal antibody in China.
Incyte and MacroGenics collaborates for anti-PD-1 monoclonal antibody biospectrumasia
October 27, 2017
Incyte gains exclusive, worldwide development and commercialization rights to MGA012 in all indications

Previous page 1 2 3 4 Next page